- Home
- AAPG vs VRDN Comparison
AAPG vs VRDN Comparison
Compare AAPG & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAPG
- VRDN
- Stock Information
- Founded
- AAPG 2009
- VRDN 2006
- Country
- AAPG China
- VRDN United States
- Employees
- AAPG N/A
- VRDN N/A
- Industry
- AAPG Biotechnology: Pharmaceutical Preparations
- VRDN Medical Specialities
- Sector
- AAPG Health Care
- VRDN Health Care
- Exchange
- AAPG Nasdaq
- VRDN Nasdaq
- Market Cap
- AAPG 1.7B
- VRDN 1.6B
- IPO Year
- AAPG 2025
- VRDN N/A
- Fundamental
- Price
- AAPG $23.04
- VRDN $12.56
- Analyst Decision
- AAPG Buy
- VRDN Buy
- Analyst Count
- AAPG 1
- VRDN 12
- Target Price
- AAPG N/A
- VRDN $36.44
- AVG Volume (30 Days)
- AAPG 26.1K
- VRDN 718.2K
- Earning Date
- AAPG 03-27-2025
- VRDN 05-07-2025
- Dividend Yield
- AAPG N/A
- VRDN N/A
- EPS Growth
- AAPG N/A
- VRDN N/A
- EPS
- AAPG N/A
- VRDN N/A
- Revenue
- AAPG $134,352,180.00
- VRDN $302,000.00
- Revenue This Year
- AAPG $328.14
- VRDN N/A
- Revenue Next Year
- AAPG N/A
- VRDN $17,629.40
- P/E Ratio
- AAPG N/A
- VRDN N/A
- Revenue Growth
- AAPG 341.77
- VRDN N/A
- 52 Week Low
- AAPG $16.50
- VRDN $11.40
- 52 Week High
- AAPG $23.37
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- AAPG N/A
- VRDN 28.07
- Support Level
- AAPG N/A
- VRDN $14.03
- Resistance Level
- AAPG N/A
- VRDN $15.91
- Average True Range (ATR)
- AAPG 0.00
- VRDN 0.67
- MACD
- AAPG 0.00
- VRDN -0.19
- Stochastic Oscillator
- AAPG 0.00
- VRDN 0.71
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.